In the treatment of multiple sclerosis (MS), disease-modifying therapies (DMTs) are pursued aggressively and early, with the goal of achieving no evidence of disease activity (NEDA).17-20* MS exacerbation, or relapse, represents active disease, and for approximately 36% of MS patients, it is still a reality at an average of 1 every 3 years despite DMT use.1†And since MS relapse has been shown to lead to measurable residual deficits in patients, it should be treated with the same urgency as MS itself in an effort to reduce the impact.21,22
Watch as patients and physicians expand on the risk and impact of MS relapse:
*NEDA is a composite that consists of multiple endpoints, namely, absence of clinical relapses, no sustained Expanded Disability Status Scale (EDSS) progression, and absence of new or enlarging T2 or T1 gadolinium-enhancing lesions confirmed by annual magnetic resonance imaging (MRI).18-20
†Estimated annual relapse rates (ARR) and percent of patients experiencing relapses in disease-modifying therapy (DMT) clinical trials as reported in product PIs.
MS relapse may lead to measurable residual deficits in patients. Two studies that analyzed the Expanded Disability Status Scale (EDSS) score during and following MS relapse in the placebo arms of various MS clinical trials found that21,22:
Scores increased by 0.5 points in nearly half of the patient population
Scores increased by 1.0 point in nearly a third of the patient population
You can help patients understand that MS relapses signal active disease, so they can appreciate the need to rapidly address any relapses. The first step is to help them know how to recognize a relapse and when they should visit you for treatment. The more planning you and your patient can do, the better the chance of identifying and treating relapses as they occur.
However, just as patients may need to try different DMTs to find one that provides optimal results for them, patients may need to try multiple MS relapse treatments before they find one that works well for them.24-30 That’s why it’s important to monitor progress toward treatment goals and adjust treatment accordingly.24
H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.
Warning and Precautions
Please see full Prescribing Information for additional Important Safety Information.